期刊文献+
共找到4,196篇文章
< 1 2 210 >
每页显示 20 50 100
文章速递抗病毒锦纶6 FDY的制备及其性能 认领
1
作者 郑幼丹 《纺织导报》 CAS 北大核心 2021年第4期47-50,共4页
赋予纺织品抗病毒功能可在一定程度上遏制病毒的传播。文章通过添加含有表面负载银纳米颗粒的介孔二氧化钛制成的锦纶6母粒制备得到抗病毒锦纶6 FDY,研究了纤维的抗病毒活性以及不同抗病毒母粒添加量对纤维性能及生产情况的影响。结果表... 赋予纺织品抗病毒功能可在一定程度上遏制病毒的传播。文章通过添加含有表面负载银纳米颗粒的介孔二氧化钛制成的锦纶6母粒制备得到抗病毒锦纶6 FDY,研究了纤维的抗病毒活性以及不同抗病毒母粒添加量对纤维性能及生产情况的影响。结果表明:抗病毒母粒的添加赋予了纤维抗病毒活性,但会造成锦纶6的相对分子质量减小、分子量分布变宽、力学性能下降、可纺性与条干不匀率变差,对染色均匀性影响不大,对纤维的沸水收缩率具有改善作用。当添加量为4%时,抗病毒锦纶6 FDY的抗病毒活性率达到99.97%,其物性指标能满足使用要求且纺况较好。 展开更多
关键词 抗病毒 锦纶6 抗病毒活性 纳米颗粒 功能性纤维
在线阅读 下载PDF
Histopathology and the predominantly progressive,indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy 认领
2
作者 Rui Huang Hui-Ying Rao +5 位作者 Ming Yang Ying-Hui Gao Jian Wang Qian Jin Dan-Li Ma Lai Wei 《世界胃肠病学杂志:英文版》 SCIE CAS 2021年第5期404-415,共12页
BACKGROUND Histological changes after direct-acting antivirals(DAAs)therapy in hepatitis C virus(HCV)patients has not been elucidated.Whether the predominantly progressive,indeterminate and predominately regressive(P-... BACKGROUND Histological changes after direct-acting antivirals(DAAs)therapy in hepatitis C virus(HCV)patients has not been elucidated.Whether the predominantly progressive,indeterminate and predominately regressive(P-I-R)score,evaluating fibrosis activity in hepatitis B virus patients has predictive value in HCV patients has not been investigated.AIM To identify histological changes after DAAs therapy and to evaluate the predictive value of the P-I-R score in HCV patients.METHODS Chronic HCV patients with paired liver biopsy specimens before and after DAAs treatment were included.Sustained virologic response(SVR)was defined as an undetectable serum HCV RNA level at 24 wk after treatment cessation.The Ishak system and P-I-R score were assessed.Inflammation improvement and fibrosis regression were defined as a≥2-points decrease in the histology activity index(HAI)score and a≥1-point decrease in the Ishak fibrosis score,respectively.Fibrosis progression was defined as a≥1-point increase in the Ishak fibrosis score.Histologic improvement was defined as a≥2-points decrease in the HAI score without worsening of the Ishak fibrosis score after DAAs therapy.The P-I-R score was also assessed.“absolutely reversing or advancing”was defined as the same directionality implied by both change in the Ishak score and posttreatment P-I-R score;and“probably reversing or advancing”was defined as only one parameter showing directionality.RESULTS Thirty-eight chronic HCV patients with paired liver biopsy specimens before and after DAAs treatment were included.The mean age of these patients was 40.9±14.6 years and there were 53%(20/38)males.Thirty-four percent(13/38)of patients were cirrhotic.Eighty-two percent(31/38)of patients achieved inflammation improvement.The median HAI score decreased significantly after SVR(pretreatment 7.0 vs posttreatment 2.0,Z=-5.146,P=0.000).Thirty-seven percent(14/38)of patients achieved fibrosis improvement.The median Ishak score decreased significantly after SVR(pretreatment 4.0 vs postt 展开更多
关键词 Hepatitis C virus Direct-acting antiviral agents Necroinflammation Fibrosis Predominantly progressive indeterminate and predominately regressive score HISTOPATHOLOGY
在线阅读 免费下载
人参对预防新冠肺炎的潜在作用研究进展 认领
3
作者 王影 徐芳菲 +3 位作者 查琳 王国明 娄子恒 曹志强 《人参研究》 2021年第2期56-61,共6页
新型冠状病毒(2019-nCoV)在全球肆虐,造成巨大人员伤亡,世界卫生组织将2019-nCoV所致疾病命名为新型冠状病毒肺炎(简称“新冠肺炎”,coronavirus disease 2019,COVID-19)。新冠肺炎因感受疫戾之气将其归入中医“疫病”范畴,病位在肺和/... 新型冠状病毒(2019-nCoV)在全球肆虐,造成巨大人员伤亡,世界卫生组织将2019-nCoV所致疾病命名为新型冠状病毒肺炎(简称“新冠肺炎”,coronavirus disease 2019,COVID-19)。新冠肺炎因感受疫戾之气将其归入中医“疫病”范畴,病位在肺和/或脾,中医药干预的优势在于可调节人体免疫功能,激发机体自身防御抵抗能力,达到祛邪与扶正固本相结合,从而截断病情发展。因此,提高自身免疫能力,补益类中药成为一个重要选择。人参作为“百草之王”具有悠久的药用历史,是我国传统名贵中草药,具有多种药理活性。本研究通过对人参的免疫调节、抗病毒和抗炎等功效作用进行综述,以期为人参更好的用于新冠肺炎的防控和临床治疗提供参考。 展开更多
关键词 新型冠状病毒肺炎 人参 免疫 抗病毒 抗炎
在线阅读 免费下载
石蒜碱药理作用的研究现状 认领
4
作者 陈茂杨 顾志良 《中国临床药理学杂志》 CAS CSCD 北大核心 2021年第4期469-472,共4页
石蒜碱是一种普遍存在于石蒜科植物中的异喹啉类生物碱,现已发现其具有多种生物学活性。本文主要从抗癌、抗病毒、抗炎和调控脂质合成等方面阐述和探讨其作用机制,以期为石蒜碱在这些疾病中的潜在应用提供新的思路和依据。
关键词 石蒜碱 药理作用 抗癌 抗病毒
Crystal structure of SARS-CoV-2 papain-like protease 认领 被引量:1
5
作者 Xiaopan Gao Bo Qin +5 位作者 Pu Chen Kaixiang Zhu Pengjiao Hou Justyna Aleksandra Wojdyla Meitian Wang Sheng Cui 《药学学报:英文版》 SCIE CAS CSCD 2021年第1期237-245,共9页
The pandemic of coronavirus disease 2019(COVID-19)is changing the world like never before.This crisis is unlikely contained in the absence of effective therapeutics or vaccine.The papain-like protease(PLpro)of severe ... The pandemic of coronavirus disease 2019(COVID-19)is changing the world like never before.This crisis is unlikely contained in the absence of effective therapeutics or vaccine.The papain-like protease(PLpro)of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)plays essential roles in virus replication and immune evasion,presenting a charming drug target.Given the PLpro proteases of SARS-CoV-2 and SARS-CoV share significant homology,inhibitor developed for SARS-CoV PLpro is a promising starting point of therapeutic development.In this study,we sought to provide structural frameworks for PLpro inhibitor design.We determined the unliganded structure of SARS-CoV-2 PLpro mutant C111 S,which shares many structural features of SARS-CoV PLpro.This crystal form has unique packing,high solvent content and reasonable resolution 2.5 A°,hence provides a good possibility for fragment-based screening using crystallographic approach.We characterized the protease activity of PLpro in cleaving synthetic peptide harboring nsp2/nsp3 juncture.We demonstrate that a potent SARS-CoV PLpro inhibitor GRL0617 is highly effective in inhibiting protease activity of SARSCoV-2 with the IC50 of 2.2?0.3 mmol/L.We then determined the structure of SARS-CoV-2 PLpro complexed by GRL0617 to 2.6 A°,showing the inhibitor accommodates the S3 e S4 pockets of the substrate binding cleft.The binding of GRL0617 induces closure of the BL2 loop and narrows the substrate binding cleft,whereas the binding of a tetrapeptide substrate enlarges the cleft.Hence,our results suggest a mechanism of GRL0617 inhibition,that GRL0617 not only occupies the substrate pockets,but also seals the entrance to the substrate binding cleft hence prevents the binding of the LXGG motif of the substrate. 展开更多
关键词 SARS-CoV-2 PLpro Proteinase inhibitor Crystal structure Antiviral drug Drug design
二氢杨梅素抗菌、抗病毒作用的研究进展 认领
6
作者 石依姗 方建国 +1 位作者 施春阳 王景 《现代药物与临床》 CAS 2021年第2期408-413,共6页
二氢杨梅素是葡萄科蛇葡萄属植物中广泛存在的二氢黄酮醇类化合物,具有抗炎、抗肿瘤、抗氧化、降血糖、调血脂、保肝等多种活性。近年来,二氢杨梅素在抗菌、抗病毒方面的生物学活性逐渐成为人们关注的热点。针对近些年来国内外有关二氢... 二氢杨梅素是葡萄科蛇葡萄属植物中广泛存在的二氢黄酮醇类化合物,具有抗炎、抗肿瘤、抗氧化、降血糖、调血脂、保肝等多种活性。近年来,二氢杨梅素在抗菌、抗病毒方面的生物学活性逐渐成为人们关注的热点。针对近些年来国内外有关二氢杨梅素在抗菌、抗病毒方面的研究进行综述,旨在为其在抗感染方面进一步的开发和临床应用提供思路。 展开更多
关键词 二氢杨梅素 抗菌 抗病毒 研究进展
CSOG MFM Committee Guideline: Management of Hepatitis B During Pregnancy and Prevention of Mother-to-Child Transmission of Hepatitis B Virus (2020) 认领
7
作者 Maternal-Fetal Medicine Committee,Chinese Society of Obstetrics and Gynecology,Chinese Medical Association Chinese Society of Perinatal Medicine,Chinese Medical Association +4 位作者 Chinese Academy of Maternal-Fetal Medicine Yi-Hua Zhou Yali Hu Xinghui Liu Huixia Yang 《母胎医学杂志(英文)》 2021年第1期7-17,共11页
Mother-to-child transmission (MTCT) of hepatitis B virus (HBV) is the main cause of chronic hepatitis B. The prevention of MTCT plays a critical role in control chronic hepatitis B. The main purpose of the present cli... Mother-to-child transmission (MTCT) of hepatitis B virus (HBV) is the main cause of chronic hepatitis B. The prevention of MTCT plays a critical role in control chronic hepatitis B. The main purpose of the present clinical guidelines is to aid healthcare providers in managing pregnant women with positive HBsAg and in preventing MTCT of HBV. We recommend: (1) all pregnant women require prenatal screen for hepatitis B serological markers;(2) newborn infants of mothers with negative hepatitis B surface (HBsAg) require administration of hepatitis B vaccine on a 0, 1, and 6 month-schedule;(3) newborn infants of mothers with positive HBsAg need hepatitis B immunoglobulin (HBIG) and birth dose vaccine within 12 hours (the sooner the better) after birth, followed by injection of the second and third dose of hepatitis B vaccine at the age of one and six months respectively;(4) in preterm neonates or neonates with poor health conditions born to HBsAg-positive mothers, the immunoprophylaxis measures should be appropriately taken;(5) to further reduce MTCT of HBV, pregnant women with HBV DNA levels >2×105 IU/mL or positive hepatitis B e antigen may receive oral antivirals, starting from 28 to 32 weeks of gestation and discontinuing the drug on the delivery day;(6) cesarean section is not recommended to reduce MTCT of HBV;(7) breastfeeding is recommended in infants of HBsAg-positive mothers, regardless of maternally positive hepatitis B e antigen, maternal nipple injury or bleeding, oral mucosal injury in neonates or infants;(8) breastfeeding is recommended in infants born to HBsAg-positive mothers who require continuation of antiviral therapy after delivery, and the infants should be followed up to observe whether adverse effects develop;and (9) the infants born to HBsAg-positive mothers should be tested for hepatitis B serological markers at the age of 7-12 months, and those who are negative for HBsAg and anti-HBs should receive three doses of hepatitis B vaccine on the 0, 1, and 6 month-schedule as soon as possible. 展开更多
关键词 Antiviral agents Hepatitis B virus IMMUNOPROPHYLAXIS MANAGEMENT Mother-to-child transmission PREGNANCY
活血软坚扶正方联合抗病毒治疗气虚血瘀证型HBeAg阴性CHB患者肝纤维化的疗效 认领
8
作者 李月翠 胡伟跃 +1 位作者 徐象威 陈豪 《中国现代医生》 2021年第6期23-27,共5页
目的探讨活血软坚扶正方联合抗病毒治疗气虚血瘀证型HBeAg阴性慢性乙型肝炎(CHB)患者肝纤维化的疗效。方法选取2019年1—12月我院感染科收治的80例HBeAg阴性CHB患者进行研究。采用随机数字表法分为观察组和对照组,每组各40例。对照组采... 目的探讨活血软坚扶正方联合抗病毒治疗气虚血瘀证型HBeAg阴性慢性乙型肝炎(CHB)患者肝纤维化的疗效。方法选取2019年1—12月我院感染科收治的80例HBeAg阴性CHB患者进行研究。采用随机数字表法分为观察组和对照组,每组各40例。对照组采用抗病毒治疗,观察组在对照组基础上加用活血软坚扶正方治疗。治疗36周,观察两组中医证候积分、临床疗效、肝纤维化、肝功能及不良反应。结果治疗后,观察组中医证候积分低于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率为92.50%(37/40),明显高于对照组的72.50%(29/40),差异有统计学意义(P<0.05)。治疗后,观察组血清透明质酸(HA)、Ⅲ型前胶原(PⅢP)水平低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组丙氨酸氨基转移酶(ALT)水平低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组乙型肝炎病毒HBV DNA阴转率为92.50%(37/40),高于对照组的72.50%(29/40),壳多糖酶3样蛋白1(CHI3L1)水平低于对照组,差异有统计学意义(P<0.05)。观察组有4例患者发生恶心、头痛、眩晕3例,均较轻无需特殊治疗。结论活血软坚扶正方联合抗病毒治疗气虚血瘀证型HBeAg阴性CHB患者的临床疗效较好,可有效改善临床症状和肝纤维化指标,缓解肝功能,且不良反应较小。 展开更多
关键词 活血软坚扶正方 抗病毒 气虚血瘀证型 HBEAG阴性 CHB 肝纤维化
在线阅读 下载PDF
麻杏石甘汤联合西药治疗小儿肺炎咳喘临床研究 认领
9
作者 李丹 周燕 许慧 《新中医》 CAS 2021年第4期36-38,共3页
目的:观察麻杏石甘汤加减联合西药治疗小儿肺炎咳喘的临床效果。方法:将小儿肺炎咳喘患者74例,按随机数字表法分为西药组与中西医结合组各37例。西药组根据病情给予抗菌、抗病毒治疗,中西医结合组在西药组的基础上联合麻杏石甘汤治疗。... 目的:观察麻杏石甘汤加减联合西药治疗小儿肺炎咳喘的临床效果。方法:将小儿肺炎咳喘患者74例,按随机数字表法分为西药组与中西医结合组各37例。西药组根据病情给予抗菌、抗病毒治疗,中西医结合组在西药组的基础上联合麻杏石甘汤治疗。比较2组临床治疗总有效率,观察2组治疗前后中医证候积分情况、临床症状消失时间以及不良反应发生率。结果:中西医结合组总有效率为94.59%,西药组为81.08%,2组比较,差异有统计学意义(P<0.05)。治疗后,2组主症、次症中医证候积分均较治疗前降低(P<0.05),且中西医结合组主症、次症中医证候积分均低于西药组(P<0.05)。中西医结合组体温恢复正常时间、咳嗽消失时间、喘息消失时间、肺部啰音消失时间均短于西药组,差异有统计学意义(P<0.05)。中西医结合组不良反应发生率为5.41%,西药组为2.70%,2组比较,差异无统计学意义(P>0.05)。结论:麻杏石甘汤联合西药治疗对肺炎咳喘,可明显改善患儿的临床症状,提高临床治疗总有效率。 展开更多
关键词 小儿肺炎咳喘 麻杏石甘汤 抗菌 抗病毒 中医证候积分
蛇莓的化学成分、药理作用和应用 认领
10
作者 乔芊芊 张景艳 +1 位作者 张凯 李建喜 《中兽医医药杂志》 CAS 2021年第1期39-42,共4页
蛇莓属于蔷薇科植物,全株供药用,有散瘀消肿、收敛止血、清热解毒之功,现代研究发现,在医学上,蛇莓可用作抗肿瘤、抗炎、抑菌药物;在农业上,可作为植物农药、肥料等。本文主要从蛇莓的产地生境、化学成分、药理作用和应用等方面进行综述... 蛇莓属于蔷薇科植物,全株供药用,有散瘀消肿、收敛止血、清热解毒之功,现代研究发现,在医学上,蛇莓可用作抗肿瘤、抗炎、抑菌药物;在农业上,可作为植物农药、肥料等。本文主要从蛇莓的产地生境、化学成分、药理作用和应用等方面进行综述,在此基础上对蛇莓的研究前景进行展望,为进一步研究中草药蛇莓提供方向。 展开更多
关键词 化学成分 药理作用 抗肿瘤 抗氧化、抗病毒、抑菌 应用
常用预防治疗具有抗病毒生物活性的中药及其药效成分的研究进展 认领
11
作者 林燕 《海峡药学》 2021年第3期1-7,共7页
本文对中药具有抗病毒生物活性的文献进行比较系统和全面的研究分析与总结。结果显示,常用来预防及治疗抗病毒的常用中药有32种,以及总结了关于它们的抗病毒种类和有效成分。并且金银花、甘草、板蓝根、鱼腥草、连翘以及黄芩是具有抗病... 本文对中药具有抗病毒生物活性的文献进行比较系统和全面的研究分析与总结。结果显示,常用来预防及治疗抗病毒的常用中药有32种,以及总结了关于它们的抗病毒种类和有效成分。并且金银花、甘草、板蓝根、鱼腥草、连翘以及黄芩是具有抗病毒种类数量最多的中药。此外,研究发现,人参皂苷类成分、穿心莲内酯、甘草酸以及绿原酸等单体化合物是具有非常强潜力的广谱抗病毒活性中间体。总之,通过本论文的研究分析与总结,以期能为临床用于由病毒感染引起的疾病治疗的中药药物选择提供一定的参考依据。 展开更多
关键词 中药 抗病毒 药效成分
在线阅读 下载PDF
利用超分子组装理论探讨麻杏石甘汤抗病毒机制研究的新策略 认领
12
作者 陈瑞 陈志鹏 《南京中医药大学学报》 CAS CSCD 北大核心 2021年第1期136-139,共4页
汤剂中的超分子现象受到了越来越多的关注,成为中药学领域的研究热点。该文综述了近几年有关中药汤剂中的超分子现象的研究进展,并以麻杏石甘汤为例,提出从超分子角度探究麻杏石甘汤抗病毒活性的原因,为研究中药汤剂中超分子结构与药效... 汤剂中的超分子现象受到了越来越多的关注,成为中药学领域的研究热点。该文综述了近几年有关中药汤剂中的超分子现象的研究进展,并以麻杏石甘汤为例,提出从超分子角度探究麻杏石甘汤抗病毒活性的原因,为研究中药汤剂中超分子结构与药效之间的关系提供新的思路。 展开更多
关键词 超分子化学 中药汤剂 自组装 麻杏石甘汤 抗病毒
在线阅读 下载PDF
Genotype 3-hepatitis C virus’last line of defense 认领
13
作者 Dorota Zarębska-Michaluk 《世界胃肠病学杂志:英文版》 SCIE CAS 2021年第11期1006-1021,共16页
Chronic infection with hepatitis C virus(HCV)is one of the leading causes of liver disease globally,affecting approximately 71 million people.The majority of them are infected with genotype(GT)1 but infections with GT... Chronic infection with hepatitis C virus(HCV)is one of the leading causes of liver disease globally,affecting approximately 71 million people.The majority of them are infected with genotype(GT)1 but infections with GT3 are second in frequency.For many years,GT3 was considered to be less pathogenic compared to other GTs in the HCV family due to its favorable response to interferon(IFN)-based regimen.However,the growing evidence of a higher rate of steatosis,more rapid progression of liver fibrosis,and lower efficacy of antiviral treatment compared to infection with other HCV GTs has changed this conviction.This review presents the specifics of the course of GT3 infection and the development of therapeutic options for GT3-infected patients in the era of direct-acting antivirals(DAA).The way from a standard of care therapy with pegylated IFNalpha(pegIFNα)and ribavirin(RBV)through a triple combination of pegIFNα+RBV and DAA to the highly potent IFN-free pangenotypic DAA regimens is discussed along with some treatment options which appeared to be dead ends.Although the implementation of highly effective pangenotypic regimens is the most recent stage of revolution in the treatment of GT3 infection,there is still room for improvement,especially in patients with liver cirrhosis and those who fail to respond to DAA therapies,particularly those containing inhibitors of HCV nonstructural protein 5A. 展开更多
关键词 Hepatitis C virus Genotype 3 Antiviral treatment INTERFERON Direct-acting antivirals Pangenotypic
在线阅读 免费下载
Molecular Characterization and Expression Analysis of SKIV Infection of Interferon-Induced Protein with Tetratricopeptide Repeats 1(IFIT1) in Epinephelus lanceolatus 认领
14
作者 WANG Lei MA Teng +4 位作者 XU Wenteng CHEN Zhangfan ZHOU Qian ZHENG Guiliang CHEN Songlin 《中国海洋大学学报:英文版》 SCIE CAS CSCD 2021年第2期383-392,共10页
Interferon-induced protein with tetratricopeptide repeats 1(IFIT1), also known as interferon-induced protein 56(IFI56) or Interferon-stimulated protein 56(ISG56), was originally identified as a protein induced upon tr... Interferon-induced protein with tetratricopeptide repeats 1(IFIT1), also known as interferon-induced protein 56(IFI56) or Interferon-stimulated protein 56(ISG56), was originally identified as a protein induced upon treatment with interferon and inhibited by viral replication and translational initiation. In this study, Epinephelus lanceolatus IFIT1(ELIFIT1) gene was cloned for the first time. The complete cDNA of El IFIT1 gene includes 2921 nucleotides, and encodes a 437-amino acid(AA) protein. The putative ELIFIT1 protein has 9 TRP domains and is highly similar with IFIT1 proteins in other teleosts. In healthy fish, ELIFIT1 gene was highly expressed in the blood, which indicate its specific function in the peripheral immune system. Its expression was also observed in various immunity-related tissues including spleen, intestine, and kidney, Inducted with spotted knifejaw iridovirus(SKIV), ELIFIT1 gene expression was upregulated in the spleen, kidney, and liver 24 h after induction and reached its peak at 72 h, indicating that ELIFIT1 may play an important role in antivirus. These findings contribute to the understanding of the antiviral regulation of ELIFIT1 gene in teleost. 展开更多
关键词 interferon-induced protein with tetratricopeptide repeats 1(IFIT1) Epinephelus lanceolatus tetratricopeptide repeats(TPR)motif expression pattern antiviral function
在线阅读 下载PDF
Human hepatitis viruses-associated cutaneous and systemic vasculitis 认领
15
作者 Chrong-Reen Wang Hung-Wen Tsai 《世界胃肠病学杂志:英文版》 SCIE CAS 2021年第1期19-36,共18页
Human hepatitis viruses(HHVs)include hepatitis A virus,hepatitis B virus(HBV),hepatitis C virus(HCV),hepatitis delta virus,and hepatitis E virus and can cause liver inflammation in their common human host.Usually,HHV ... Human hepatitis viruses(HHVs)include hepatitis A virus,hepatitis B virus(HBV),hepatitis C virus(HCV),hepatitis delta virus,and hepatitis E virus and can cause liver inflammation in their common human host.Usually,HHV is rapidly cleared by the immune system,following acute HHV invasion.The morbidities associated with hepatitis A virus and hepatitis E virus infection occur shortly after their intrusion,in the acute stage.Nevertheless,the viral infectious process can persist for a long period of time,especially in HBV and HCV infection,leading to chronic hepatitis and further progressing to hepatic cirrhosis and liver cancer.HHV infection brings about complications in other organs,and both acute and chronic hepatitis have been associated with clinical presentations outside the liver.Vascular involvement with cutaneous and systemic vasculitis is a well-known extrahepatic presentation;moreover,there is growing evidence for a possible causal relationship between viral pathogens and vasculitis.Except for hepatitis delta virus,other HHVs have participated in the etiopathogenesis of cutaneous and systemic vasculitis via different mechanisms,including direct viral invasion of vascular endothelial cells,immune complex-mediated vessel wall damage,and autoimmune responses with stimulation of autoreactive B-cells and impaired regulatory T-cells.Cryoglobulinemic vasculitis and polyarteritis nodosa are recognized for their association with chronic HHV infection.Although therapeutic guidelines for HHV-associated vasculitis have not yet been established,antiviral therapy should be initiated in HBV and HCV-related systemic vasculitis in addition to the use of corticosteroids.Plasma exchange and/or combined cyclophosphamide and corticosteroid therapy can be considered in patients with severe life-threatening vasculitis manifestations. 展开更多
关键词 Human hepatitis viruses Hepatitis B virus Hepatitis C virus Cryogobulinemic vasculitis Polyarteritis nodosa Antiviral therapy
在线阅读 免费下载
Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy 认领
16
作者 Xiao-Yan Jiang Bing Huang +5 位作者 Dan-Ping Huang Chun-Shan Wei Wei-Chao Zhong De-Ti Peng Fu-Rong Huang Guang-Dong Tong 《世界胃肠病学杂志:英文版》 SCIE CAS 2021年第11期1101-1116,共16页
BACKGROUND China has a high prevalence of hepatitis B virus(HBV),but most chronic hepatitis B(CHB)patients do not receive standardized antiviral therapy.There are few relevant reports addressing the outcomes of the la... BACKGROUND China has a high prevalence of hepatitis B virus(HBV),but most chronic hepatitis B(CHB)patients do not receive standardized antiviral therapy.There are few relevant reports addressing the outcomes of the large number of CHB patients who do not receive antiviral therapy.AIM To observe the outcomes of long-term follow-up of patients with CHB without antiviral treatment.METHODS This study included 362 patients with CHB and 96 with hepatitis B cirrhosis without antiviral treatment and with only liver protection and anti-inflammatory treatment from 1993 to 1998.The median follow-up times were 10 and 7 years,respectively.A total of 203 CHB and 129 hepatitis B cirrhosis patients receiving antiviral therapy were selected as the control groups.The median follow-up times were 8 and 7 years,respectively.Kaplan-Meier curves were used to analyze the cumulative incidence of hepatocellular carcinoma(HCC),and the Cox regression model was used to analyze the risk factors for HCC.RESULTS Among the patients in the non-antiviral group,16.9%had spontaneous decreases(HBeAg)seroconversion.In the antiviral group,87.2%of patients had undetectable HBV DNA,and 52%showed HBeAg seroconversion.Among CHB and hepatitis B cirrhosis patients,the cumulative incidence rates of HCC were 14.9%and 53.1%,respectively,in the non-antiviral group and were 10.7%and 31.9%,respectively,in the antiviral group.There was no difference between the two groups regarding the CHB patients(P=0.842),but there was a difference between the groups regarding the hepatitis B cirrhosis patients(P=0.026).The cumulative incidence rates of HCC were 1.6%and 22.3%(P=0.022)in the groups with and without spontaneous HBeAg seroconversion,respectively.The incidence rates of HCC among patients with and without spontaneous declines in HBV DNA to undetectable levels were 1.6%and 19.1%,respectively(P=0.051).There was no difference in the cumulative incidence of HCC between the two groups regarding the patients with drug-resistant CHB(P=0.119),but there was a significant diffe 展开更多
关键词 Chronic hepatitis B Anti-inflammatory therapy Hepatoprotective therapy Cumulative incidence Hepatocellular carcinoma Antiviral therapy
在线阅读 免费下载
新型α-葡萄糖苷酶抑制剂筛选及药理作用研究进展 认领
17
作者 阎成炟 郭崇真 林建阳 《药物评价研究》 CAS 2021年第2期440-445,共6页
α-葡萄糖苷酶抑制剂能有效降低餐后血糖,为临床一线降糖用药之一。近年来报道了大量新化合物作为α-葡萄糖苷酶抑制剂,不仅可以起到降糖的作用,而且还具有抗溶酶体堆积病、抗病毒、抗菌和抗癌的药效。α-葡萄糖苷酶抑制剂新型化合物按... α-葡萄糖苷酶抑制剂能有效降低餐后血糖,为临床一线降糖用药之一。近年来报道了大量新化合物作为α-葡萄糖苷酶抑制剂,不仅可以起到降糖的作用,而且还具有抗溶酶体堆积病、抗病毒、抗菌和抗癌的药效。α-葡萄糖苷酶抑制剂新型化合物按照产出途径主要有微生物代谢产物、天然产物与化学合成产物。就近年来开发的多种类型的α-葡萄糖苷酶抑制剂及其抗癌、抗病毒和抗溶酶体堆积病作用进行了综述,旨在为α-葡萄糖苷酶抑制剂或临床前候选药物提供更好的研究方向。 展开更多
关键词 Α-葡萄糖苷酶抑制剂 2型糖尿病 作用机制 药理作用 抗病毒 抗溶酶体堆积病
Modulation of antiviral cytokine production and lung protection against influenza virus by the glycosides from Ligustrum purpurascens 认领
18
作者 Chen-Yang Li Xiao-Jun Zhong +7 位作者 Xiao-Peng Hu Qin-Chang Zhu Hai-Tao Xiao Peng Zhai Da-Hong Yao Muhammad Shahid Riaz Zhen-Dan He Xun Song 《亚洲毒理学研究》 2021年第1期23-31,共9页
Ligustrum purpurascens has been used as a traditional herb for over 2,000 years in China.This study was design to investigate the modulation of antiviral cytokines and reduction in lung inflammation of virus-infected ... Ligustrum purpurascens has been used as a traditional herb for over 2,000 years in China.This study was design to investigate the modulation of antiviral cytokines and reduction in lung inflammation of virus-infected mice by the glycosides isolated from Ligustrum purpurascens.Methods:Ligustrum purpurascens glycosides(LPG)were isolated from the leaves of Ligustrum purpurascens.Proliferation of spleen lymphocytes were investigated after LPG treatment.The in vitro and in vivo cytokine modulation of LPG was studied.Furthermore,the anti-inflammatory and antiviral activities of LPG,with the potential to reduce inflammatory lung disorders,were investigated by influenza A virus infected mice.Results:LPG could significantly promote the proliferation,and also could stimulate the production of IFN-γby spleen lymphocytes in a dose-dependent manner.IFN-γexpression level was increased significantly compared to the control and presented a dose-dependent manner in vitro.Furthermore,LPG inhibit the expression of TNF-αand IL-10,which return to normal level in the cyclophosphamide-induced mice model in vivo.Besides,the histopathological analysis indicated LPG reduced acute lung injury in mice infected with influenza virus.Conclusion:This study suggested that LPG could increase the exression of IFN-γ,immunoregulation and decrease lung inflammation of virus-infected mice. 展开更多
关键词 Ligustrum purpurascens GLYCOSIDES CYTOKINES IMMUNOREGULATION ANTIVIRAL
在线阅读 下载PDF
探讨肺结核合并乙型肝炎病毒感染患者抗病毒与护肝治疗的作用 认领
19
作者 黄肇权 《医学食疗与健康》 2021年第1期57-58,共2页
目的:在合并乙型肝炎病毒感染的肺结核患者抗病毒治疗的基础上进行护肝治疗,并分析其作用。方法:选取2017年5月至2019年4月在我院接受治疗的42例肺结核初治患者,所有患者均合并乙型肝炎病毒感染,将其分为两组。对照组21例,采取抗病毒+... 目的:在合并乙型肝炎病毒感染的肺结核患者抗病毒治疗的基础上进行护肝治疗,并分析其作用。方法:选取2017年5月至2019年4月在我院接受治疗的42例肺结核初治患者,所有患者均合并乙型肝炎病毒感染,将其分为两组。对照组21例,采取抗病毒+抗结核治疗;观察组21例,在对照组基础上进行护肝治疗。结果:观察组治疗总有效率明显高于对照组,且治疗后15d、30d的ALT、AST、TBIL水平均明显低于对照组(P<0.05);两组患者HbeAg转阴率、HBV-DNA转阴率无明显差异(P>0.05)。结论:抗病毒及抗结核治疗期间使用甘草酸二铵护肝治疗可提高治疗效果,减轻肝脏损害。 展开更多
关键词 乙型肝炎 肺结核 抗病毒
在线阅读 下载PDF
FDA已批准上市药物托伐普坦可在体内外抑制寨卡病毒感染 认领
20
作者 陈秀秀 罗荣华 +7 位作者 姚债文 郑昌博 唐秋菊 庞伟 汪芳 杨柳萌 熊思东 郑永唐 《中国药学:英文版》 CAS CSCD 2021年第3期218-229,共12页
寨卡病毒(Zika virus,ZIKV)是黄病毒属中一个被忽视的病毒。近年来,由于其与小头畸形和其他先天性缺陷疾病的关系,引起了全球的广泛关注。目前,仍没有抗ZIKV的疫苗或治疗方法批准上市。我们通过噬斑实验及MTT实验筛选鉴定出一种FDA已批... 寨卡病毒(Zika virus,ZIKV)是黄病毒属中一个被忽视的病毒。近年来,由于其与小头畸形和其他先天性缺陷疾病的关系,引起了全球的广泛关注。目前,仍没有抗ZIKV的疫苗或治疗方法批准上市。我们通过噬斑实验及MTT实验筛选鉴定出一种FDA已批准上市药物--托伐普坦,具有抗亚洲谱系寨卡病毒活性且细胞毒性很低。病毒产量降低实验和蛋白印迹实验也进一步证实了托伐普坦的抗寨卡病毒活性。分时给药实验表明托伐普坦在细胞感染ZIKV后6到14 h发挥抗ZIKV活性,即作用于ZIKV生命周期的进入后阶段。此外,托伐普坦对非洲普系寨卡病毒也具有抑制作用,表明托伐普坦的抗ZIKV活性并不是毒株依赖性的。值得注意的是,托伐普坦还可降低ZIKV感染小鼠的死亡率。因此,托伐普坦是一个潜在的抗ZIKV治疗药物,值得进一步研究。 展开更多
关键词 寨卡病毒 托伐普坦 抗病毒 小头畸形 黄病毒属
上一页 1 2 210 下一页 到第
使用帮助 返回顶部 意见反馈